|Day Low/High||239.77 / 246.74|
|52 Wk Low/High||208.07 / 287.94|
As CVS Health's stock continues to run, management's careful approach should be encouraging for beleaguered investors.
The fear will subside around health care stocks, and here is why.
I've spotlighted three blue-chip companies with stock prices that are at ridiculously low valuations right now.
Insurance companies would have their claws in any potential new healthcare law so deep, the law will have slash marks on it.
Especially when healthcare CEOs discus political issues with analysts and reporters.
This health care selloff shows the value of diversification to protect our portfolios -- and to go on the offensive and find bargains.
There is a bloodbath of selling in medical-related names and severe pressure on cloud-related stocks that have been momentum favorites.
Recapping a big day of earnings for both names.
A resilient market allows you to buy stocks when they get hammered and do so with some certainty that you won't get your head handed to you.
The free press that the progressive push for Medicare got on Tuesday morning is hurting the healthcare sector.
UNH's operational strength can't overcome the potential political overhang at the moment.
This is not a stock you want to play around with on the long side.
The health benefit giant's fundamentals are good, but there are more symptoms to consider for a proper examination.
When Netflix reports earnings tonight, what will likely matter above all else for now will be subscriber growth.
Warren Buffett's big bet on kidney dialysis provider DaVita may finally be primed to start paying off, albeit after five frustrating years of negative returns.
Two items are forcing the marketplace to take note as the morning unfolds. One, We already know that the Trump administration has long opposed the Affordable Care Act. The president has at least been smart enough to insinuate that the GOP not take t...
It becomes difficult to own for anything other than a trade, managed care stocks and those that most benefit from Medicare expansion.
I think sometimes the best way to parse the temperament is to go over the most obviously 'wrong' moves and address why they might not be wrong at all.
National security is job one. Cutting a nice deal with China that benefits both sides must come second.
If we didn't know where the algorithms that now control the point of sale were lined up before Monday, we sure know now.
Let's see what we can glean from the charts and indicators.
Pharmacy Benefit Managers (PBMs) are in for some problems if proposed regulation is given approval.